Susceptibility to antibiotics of Escherichia coli isolated from community-acquired urinary tract infections;Sensibilité aux antibiotiques des Escherichia coli isolé;s d'infections urinaires communautaires

Medecine et Maladies Infectieuses

Volumn 40, Issue 10, 2010, Pages 555-559

  Fabre, R ^a   Merens A ^b   Lefebvre, F ^c   Epifanoff, G ^a   Cerutti, F ^a   Pupin, H ^a   Tardif, D ^a   Cavallo, J D ^b   Ternois, I ^a  

^a Label Bio   (France)

^b SERVICE D ENDOCRINOLOGIE   (France)

^c DRASS Normandie   (France)

Author keywords

Antibiotics susceptibility; Community acquired urinary tract infections; Escherichia coli

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; NALIDIXIC ACID; NITROFURANTOIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGING; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMMUNITY ACQUIRED URINARY TRACT INFECTION; ESCHERICHIA COLI; FEMALE; FRANCE; HUMAN; MALE; NONHUMAN; SEX DIFFERENCE; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; CHILD; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 77958508446     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.03.002     Document Type: Article

References (11)

1. Robba L, Kuhn A, Vielfaure N, Rigollot N. Les données 2007 du codage de la biologie médicale. CNAMTS points de repère; no 19, octobre 2008.
2. Agence française de sécurité sanitaire des produits de santé. Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires chez l'adulte ; 2008. http://www.afssaps.sante.fr/.
3. Agence française de sécurité sanitaire des produits de santé. Diagnostic et antibiothérapie des infections urinaires bactériennes communautaires du nourrisson et de l'enfant ; 2007. http://www.afssaps.sante.fr/.
4. Comité de l'antibiogramme de la Société française de microbiologie. Recommandations 2008. http://www.sfm.asso.fr/.
5. Naber K.G., Schito G., Botto H., Palou J., Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008, 54(5):1164-1175.
6. De Mouy D., Fabre R., Cavallo J.D., Arzouni J.P., Baynat M., Bicart-See A., et al. Community-acquired urinary tract infections in 15 to 65 years old female patients in France. Susceptibility of E. coli according to history: AFORCOPI-BIO network 2003. Med Mal Infect 2007, 37(9):594-598.
7. Gobernado M., Valdés L., Alós J.I., Garcia-Rey C., Dal-Ré R., García-de-Lomas J., et al. Quinolone resistance in female outpatient urinary tract isolates of Escherichia coli: age-related differences. Rev Esp Quimioter 2007, 20(2):206-210.
8. Fadda G., Nicoletti G., Schito G.C., Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 2005, 17(3):251-257.
9. Pitout J.D., Nordmann P., Laupland K.B., Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005, 56(1):52-59.
10. De Mouy D, Mérens A, Cavallo JD, Galinier JL, Gontier D, Pfeffer J, et al. Sensibilité de E. coli aux quinolones et aux céphalosporines de troisième génération (C3G) dans les infections urinaires communautaires: étude AFORCOPI-BIO 2008. In: 28e Réunion interdisciplinaire de chimiothérapie anti-infectieuse ; Paris, France.
11. De Backer D., Christiaens T., Heytens S., De Sutter A., Stobberingh E.E., Verschraegen G. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval. J Antimicrob Chemother 2008, 62(2):364-368.